Background: Breast cancer is the most common invasive cancer among women 25 worldwide. Next-generation sequencing (NGS) has revolutionized the study of cancer 26 across research labs around the globe, however genomic testing in clinical settings 27 remain limited. Advances in sequencing reliability, pipeline analysis, accumulation of 28 relevant data, and the reduction of costs are rapidly increasing the feasibility of NGS-29 based clinical decision making. 30
Background 53
Advanced breast cancer is currently incurable. Selection of systematic therapies is 54 primarily based on clinical and histological features and molecular subtype, as 55 defined by clinical assays [1] . Large-scale genomic studies have shed light into the 56 heterogeneity of breast cancer and its evolution to advanced disease [2, 3] , and 57 coupled with the rapid advancement of targeted therapies, highlights the need for 58 more sophisticated diagnostics in cancer management [4] . 59
Next-generation sequencing (NGS) based diagnostics allow clinicians to identify 60 specific putative driver events in individual tumors. Correctly identifying disease 61 drivers may enable clinicians to better predict treatment responses, and significantly 62 improve patient care [5] . However, to date, the use of NGS as a clinical diagnostic 63 remains limited [6] . Published data regarding prognostic utility, and utilization for 64 selection of targeted therapies or enrolment clinical trials is lacking. 65
The original 46 gene AmpliSeq Cancer Hotspot Panel (Thermo Fisher Scientific) was 66 shown to have a diagnostic suitability in primary lung, colon, and pancreatic cancers 67 [7] , however, our previous report that surveyed the clinical usefulness of the 50 gene 68
AmpliSeq Cancer Hotspot Panel V2 in breast cancer found that the panel lacks 69 numerous key known drivers of advanced breast cancer [8] . For example, the panel 70
does not include any amplicons in ESR1, which harbor mutations which are known to 71 contribute to hormone therapy resistance (for review see [9] ), and lacks coverage of 72 the majority of known driver mutations in ERBB2 [10] . 73
The lack of any reported breast cancer specific diagnostic NGS test inspired the 74 development of MammaSeq TM , an amplicon based NGS panel built specifically for use 75 in advanced breast cancer. 46 solid tumor samples from women with advanced breast 76 cancer, plus an additional 14 samples of circulating-free DNA (cfDNA) from patients 77 with metastatic breast cancer were used in this pilot study to define the clinical utility 78 of the panel. The patient cohort encompassed all 3 major molecular subtypes of breast 79 cancer (luminal, ERBB2 positive and triple negative), and both lobular and ductal 80 carcinomas (Table 1) . 81
Methods: 82

Patient Sample Collection 83
For MammaSeq NGS testing, this study utilized breast tumors from 46 patients and 84 blood samples from 7 patients. The research was performed under the University of 85 Pittsburgh IRB approved protocol PRO16030066. The general patient characteristics 86 are shown in Table 1 and more detailed patient information is shown in Supplemental 87 Table 1 . We utilized 46 of the 48 breast cancer cases previously described in a report 88 by Gurda et al [8] . All of these cases underwent AmpliSeq Cancer Hotspot Panel v2 89 NGS testing between January 1, 2013 and March 31, 2015 within the UPMC health 90 system. MammaSeq TM was performed on the identical genomic DNA isolated from 91 these tumor specimens that was originally used for initial cinical testing. 2 cases were 92 excluded due to insufficient DNA. In addition, a cohort of 7 patients with metastatic 93 breast cancer (MBC) had 20ml venous blood drawn in Streck Cell-Free DNA tubes 94 between July 1, 2014 and March 29, 2016. All patients signed informed consent, and 95 samples were acquired under the University of Pittsburgh IRB approved protocol 96 (IRB0502025). We previously reported on the detection of ESR1 mutations in cfDNA 97 from these 7 patients using ddPCR [11] . Serial blood draws (range; 2-5) were 98 available for 4 patients. A total of 14 blood samples from 7 patients were utilized for 99 cfDNA and buffy coat DNA isolation, followed by NGS testing. 100
Patient Sample Processing 101 cfDNA was isolated as described previously [11] . Blood was processed to separate 102 plasma and buffy coat by double centrifugation within 4 days of blood collection. 1ml 103 to 4ml of plasma was used for isolation of cfDNA using QIAamp Circulating Nucleic 104 Acid kit (Qiagen). cfDNA was quantified using Qubit dsDNA HS assay kit 105 (ThermoFisher Scientific). Genomic DNA was isolated from buffy coat using DNeasy 106 figures 1 and 3A [14] . CNVKit was used to call copy number across all genes, however 129 only genes containing more than 3 amplicons were reported (Table 2) [15] . DNA from 130 the buffy coat of the cfDNA cohort was used to generate a single copy-number 131 reference which was used as a baseline for copy number calling on the solid tumor 132 cohort. CNKit reports copy number as a log2 ratio change. CNV were considered 133 significant above an absolute copy number above 6 ( log2(6/2)=1.58) or below 1 134 (log2(1/2) = -1 ). 135
Data and code 136
Annotated, unfiltered, mutation and CNV data, along with R code related to this study, 137 are deposited on GitHub. (https://github.com/smithng1215) 138 ddPCR 139 2 ng of cfDNA or buffy coat DNA was subjected to targeted high-fidelity 140 preamplification for 15 cycles using custom designed primers (Supplemental Table  141 2) and PCR conditions previously described [11] . Targeted preamplification products 142 were purified using QIAquick PCR Purification kit (Qiagen) and diluted at 1:20 before 143 use in ddPCR reaction. 1.5ul of diluted preamplified DNA was used as input for ddPCR 144 reaction. ddPCR was performed for ESR1-D538G, FOXA1-Y175C, and PIK3CA-145 H1047R mutations. Custom ddPCR assays were developed for ESR1-D538G 146 (Integrated DNA Technologies) and FOXA1-Y175C (ThermoFisher Scientific). 147
Sequences are described in Supplementary Table 3 . PIK3CA-H1047R was analyzed 148 using PrimePCR ddPCR assay (Bio-Rad Laboratories) dHsaCP2000078 (PIK3CA)/ 149 dHsaCP2000077 (H1047R). Nuclease-free water and buffy coat-derived wildtype 150 genomic DNA as negative controls, and oligonucleotides carrying mutation of interest 151 or DNA from a cell line with mutation as positive controls were included in each run 152 to eliminate potential false positive mutant signals. An allele frequency of 0.1% was 153 used as a lower limit of detection. 154
Statistical Analysis 155
All statistical analysis was performed in R 3.4.2. To determine if there was a 156 significant correlation between mutational burden and copy number burden, we 157 calculated the pearson correlation coefficient between the number of somatic 158 mutations in each sample, with the number of significant copy number changes in 159 each sample.
Results 161
Development of MammaSeq TM Panel 162
To build a comprehensive list of somatic mutations in breast cancer, we combined 163 mutation calls from primary tumors in TCGA (curated list level 2.1.0.0) and limited 164 studies focused on metastatic breast cancer [16] [17] [18] . The biological function and 165 druggablity of mutated genes were investigated via Gene Ontology (GO) [19] and 166 DGIdb (v2.0) databases [20] . The information regarding FDA approved drugs was 167 downloaded from "https://www.fda.gov/Drugs" and added to our list. We used the 168 following criteria to priotrize the clinically important mutated genes: 169
• The mutated gene is among significantly mutated genes (SMGs) in primary 170 and metastatic samples. 171
• The mutated gene is clinically actionable (e.g. there is available FDA-approved 172 drug(s) against it). 173
• The mutated gene is of functional importance in cancer (e.g. kinase genes 174 were scored higher in the list). 175
• The mutation has been found in more than 5 primary tumors OR 2 metastatic 176 tumors. 177
• The mutation has been found in both primary and metastatic lesions. 178
The final mutation list was then curated and narrowed down to 80 genes and 1398 179 mutations. Additional amplicons were added to select genes to ensure sufficient 180 coverage of genes known to harbor functional copy-number variants. Amplicon probe design was unsuccessful for 29 mutations, including all 3 mutations in the gene HLA-182 A, yielding a final panel consisting of 688 amplicons targeting 1369 mutations across 183 79 genes. (Selected genes described in Table 2 
Characterization of Genetic Variants detected by Mammaseq in a Solid Tumor 200
Cohort 201
To evaluate performance in mutation detection by the MammaSeq TM panel, 202 sequencing was carried out on a cohort of 46 solid tumor samples, with a mean read 203 depth of 2311X (Supplemental Figure 3 ). 4970 total variants (mean: 106, median: 204 82) were called across all patient samples. We removed identical genomic variants 205 that were present in more than 10 samples as these were likely to be sequencing 206 artifacts or common SNPs. Removing non-coding and synonymous variants yielded 207 1433 and 901 variants, respectively. To filter out less common polymorphisms, we 208 removed variants annotated in ExAC [12] or the 1000Genomes [13] databases in 209 more than 1% of the population. We removed variants with an allele frequency above 210 90% as these were likely germline. Finally, to focus on high confidence mutations, we 211 removed variants with a strand bias outside of the range of 0.5-0.6, yielding a total of 212 592 protein coding mutations (mean 12.9, median 3, IQR 3) ( Figure 1 ). 213
Interestingly, as noted by the variation between the mean and median, the total 214 number of mutations was skewed toward a subset of samples ( Figure 1-top panel) . 215 408 of the 592 mutations (69%) were found in just 4 of the 46 samples (Supplemental 216 Figure 4 ). These 4 samples are by definition outliers, as they are all more than 1.5 217 times the IQR plus the median. 3 of these 4 samples with high mutational burden were 218 of triple negative subtype, the fourth being ER + /HER2 + . The most common mutated 219 genes were TP53 (57%) and PIK3CA (43%). We also noted common mutations in 220 ESR1 (21%), ATM (21%) and ERBB2 (17%). 221
To examine CNV changes, we established a baseline for pull down and amplification 222 efficiency by performing MammaSeq TM on normal germline DNA from 14 samples (7 223 patients -6 additional). CNVkit [15] was used to pool the normal samples into single 224 reference and then call CNV in the solid tumor cohort (Figure 1) . CNV were identified 225 in many common oncogenes including CCND1, MYC, FGFR1 and others. 2 of the 3 226 ERBB2 + samples (via clinical assay) showed CNV by MammaSeq. FGF19 and CCND1 227 were co-amplified in 9 of the 46 (20%) solid tumors. Both genes are located on 11q13, 228 a band identified in GWA studies as harboring variants, including amplifications, 229 associated with ER + breast cancers [22] . There wasn't a correlation between 230 mutational burden and copy number burden (pearson correlation p-value = 0.7445). 231
Clinical Utility of Genetic Variants Detected by MammaSeq 232
To determine how many of the mutations have putative clinical utility, we utilized the 233
OncoKB precision oncology knowledge database [23] . 25 of the genes in the 234 MammaSeq TM panel (32% of the panel) harbor clinically actionable variants with 235 supporting clinical evidence (OncoKB levels 1-3). In total, we identified 28 actionable 236 variants (26 SNV and 2 ERBB2 amplifications) that have supporting clinical evidence 237 (level 1-3) and an additional 3 actionable variants supported by substantial research 238 evidence (level 4) in the solid tumor cohort (Table 3 ). The 26 SNVs were distributed 239 across 20 of the 46 cases (43%) (Figure 2) . Consistent with the report detailing the 240 development of the OncoKB database [24], the vast majority of actionable variants in 241 breast cancer are annotated at level 3, indicating that variants have been used as 242 biomarkers in Clinical Trials, however they are not FDA approved. In fact, the only 243 level 1 annotated variant in breast cancer is ERBB2 amplification. 244
Characterization of Genetic Variants detected by Mammaseq in cfDNA 245
To examine the potential of MammaSeq TM to detect variants in cfDNA, we sequenced 246 14 cfDNA samples isolated from 7 patients with metastatic disease. cfDNA samples 247 were sequenced to a mean depth of 1810X, while matched buffy gDNA was sequenced 248 to a mean depth of 425X (Supplemental figure 4) . 249
We applied the same filtering pipeline to the cfDNA variants and solid tumor variants, 250 except in the smaller cohort we removed all identical variants found in more than 4 251 samples, and lowered the minimum allele frequency to 1.0%. We identified a total of 252 43 somatic mutations across the 14 cfDNA samples (mean: 3.1, median 1, IQR 1.75) 253 ( Figure 3A ). Similar to the solid tumor cohort, a single draw from 1 patient (CF_28-254 Draw 1) harbored 25 of the 13 (58%) total mutations. Using the same definition, this 255 sample is also an outlier. Similar to the solid tumor cohort, PIK3CA and ESR1 were 256 among the most commonly mutated genes. 257
Two of the identified somatic mutations (each identified in 2 draws from 1 patient) 258 are annotated at level 3 in the OncoKB database, ESR1 -D538G and PIK3CA -H1047R 259 ( Figure 3A ). The ESR1 mutation was identified in 2 separate blood draws from patient 260 CF_28 taken 13 months apart. Interestingly, the FOXA1 -Y175C mutation was also 261 identified in the same draws from patient CF_28 ( Figure 3B ). The allele frequencies 262 of these mutations strongly correlate with levels of cancer antigen 27-29 (CA-27.29), 263 indicating that the mutation frequencies are likely an indicator of disease burden. 264 Mutations identified in all three genes (ESR1, PIK3CA, and FOXA1) were 265 independently validated using ddPCR (Supplemental Figure 5 ).
Discussion 267
Advances in the accuracy, cost, and analysis of NGS make it an ideal platform to 268 develop diagnostics that can be used to precisely identify treatment options. 269
MammaSeq was developed to comprehensively cover known driver mutation 270 hotspots specifically in primary and metastasis breast cancer that would identify 271 mutations with potential prognostic value. Typically, NGS diagnostics are reserved 272 for late stage disease. As a result, (as noted in our previous publication[8]), the solid 273 tumor cohort was significantly enriched for metastatic disease and markers of poor 274 prognosis -triple negative subtype, late presentation, and therapy resistance. 275
Consistent with previous mutational studies, we report that a small subset of breast 276 cancers harbor high mutational burden [25] . Across a variety of cancers, groups have 277 demonstrated the correlation between the tumor mutation burden (TMB) and the 278 efficacy of immunotherapy checkpoint inhibitors (reviewed here [26] to whole exome based studies. That being said, the stark difference in the total 287 number of mutations identified in the subset of 4 tumor samples, suggests that they 288 may be suited for immunotherapy. 289
Liquid biopsies are beginning to be utilized clinically after numerous proof-of-290 principle studies have demonstrated the potential of circulating cell-free DNA 291 (cfDNA) for prognostication, molecular profiling, and monitoring disease burden [11, 292 29-33] . We have demonstrated that the MammaSeq TM panel can be used to identify 293 mutations in cfDNA. For one patient (CF_28), we have cfDNA data from 5 blood draws 294 taken over the course of 13 months. The sharp drop-off in the number of somatic 295 mutations identified between the first and second draws co-occurs with a decrease in 296 CA.27.29 levels, suggesting that the patient may have responded well to treatment, 297 leading to disappearance of sensitive clones. In the later blood draws, we did not 298 observe an increase in the total number of somatic mutations, however, we did find 299 an increase in the allele frequency of ESR1-D538G and FOXA1-Y175C mutations, 300 which may be caused by therapeutic selection of resistant clones. 301
High-throughput genotyping of solid tumors and continual monitoring of disease 302 burden through sequencing of cfDNA represent potential clinical applications for NGS 303 technologies. It should be noted that targeted DNA sequencing panels such as 304 MammaSeq TM are far less comprehensive than whole exome sequencing and they do 305 not allow for evaluation of structural variants, which can often lead to gene fusions 306 that function as drivers [34] . Nevertheless, as a focused panels represent cost-307 effective and useful alternatives to whole exome sequencing for targeted mutation 308 detection.
Conclusions 310
Here we report the development of MammaSeq TM , a targeted sequencing panel 311 designed based on current knowledge of the most common, impactful, and targetable 312 drivers of metastatic breast cancer. This data provides further evidence for the use of 313 NGS diagnotsics in the management of advanced breast cancers. 314 
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